Serum Levels of Annexin A2 as a Candidate Biomarker for Hepatic Fibrosis in Patients With Chronic Hepatitis B

Authors Information
Article Notes and Dates
To Cite : Kolgelier S, Demir N A, Inkaya A C, Sumer S, Ozcimen S, et al. Serum Levels of Annexin A2 as a Candidate Biomarker for Hepatic Fibrosis in Patients With Chronic Hepatitis B, Hepat Mon. 2015 ;15(10):e30655. doi: 10.5812/hepatmon.30655.
Copyright: Copyright © 2015, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Pungpapong S, Kim WR, Poterucha JJ. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc. 2007; 82(8): 967-75[DOI][PubMed]
  • 2. Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int. 2009; 29 Suppl 1: 100-7[DOI][PubMed]
  • 3. Ji NY, Park MY, Kang YH, Lee CI, Kim DG, Yeom YI, et al. Evaluation of annexin II as a potential serum marker for hepatocellular carcinoma using a developed sandwich ELISA method. Int J Mol Med. 2009; 24(6): 765-71[PubMed]
  • 4. Zhao Y, Ben H, Qu S, Zhou X, Yan L, Xu B, et al. Proteomic analysis of primary duck hepatocytes infected with duck hepatitis B virus. Proteome Sci. 2010; 8: 28[DOI][PubMed]
  • 5. Suzuki S, Tanigawara Y. Forced expression of S100A10 reduces sensitivity to oxaliplatin in colorectal cancer cells. Proteome Sci. 2014; 12: 26[DOI][PubMed]
  • 6. Deng S, Wang J, Hou L, Li J, Chen G, Jing B, et al. Annexin A1, A2, A4 and A5 play important roles in breast cancer, pancreatic cancer and laryngeal carcinoma, alone and/or synergistically. Oncol Lett. 2013; 5(1): 107-12[DOI][PubMed]
  • 7. Mohammad HS, Kurokohchi K, Yoneyama H, Tokuda M, Morishita A, Jian G, et al. Annexin A2 expression and phosphorylation are up-regulated in hepatocellular carcinoma. Int J Oncol. 2008; 33(6): 1157-63[PubMed]
  • 8. Baranova A, Lal P, Birerdinc A, Younossi ZM. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol. 2011; 11: 91[DOI][PubMed]
  • 9. Parkes J, Guha IN, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol. 2006; 44(3): 462-74[DOI][PubMed]
  • 10. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD, American Association for the Study of Liver D. Liver biopsy. Hepatology. 2009; 49(3): 1017-44[DOI][PubMed]
  • 11. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995; 22(6): 696-9[PubMed]
  • 12. Zhang L, Peng X, Zhang Z, Feng Y, Jia X, Shi Y, et al. Subcellular proteome analysis unraveled annexin A2 related to immune liver fibrosis. J Cell Biochem. 2010; 110(1): 219-28[DOI][PubMed]
  • 13. Ibrahim AM, Hashem ME, Mostafa EF, Refaey MM, Hamed EF, Ibrahim I, et al. Annexin A2 versus Afp as an efficient diagnostic serum marker for hepatocellular carcinoma. J Gastroenterol Hepatol Res. 2013; 2(9): 780-5
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check